JP2022537214A5 - - Google Patents

Info

Publication number
JP2022537214A5
JP2022537214A5 JP2021576258A JP2021576258A JP2022537214A5 JP 2022537214 A5 JP2022537214 A5 JP 2022537214A5 JP 2021576258 A JP2021576258 A JP 2021576258A JP 2021576258 A JP2021576258 A JP 2021576258A JP 2022537214 A5 JP2022537214 A5 JP 2022537214A5
Authority
JP
Japan
Application number
JP2021576258A
Other languages
Japanese (ja)
Other versions
JP2022537214A (ja
JPWO2020257707A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038813 external-priority patent/WO2020257707A1/en
Publication of JP2022537214A publication Critical patent/JP2022537214A/ja
Publication of JP2022537214A5 publication Critical patent/JP2022537214A5/ja
Publication of JPWO2020257707A5 publication Critical patent/JPWO2020257707A5/ja
Pending legal-status Critical Current

Links

JP2021576258A 2019-06-21 2020-06-19 メープルシロップ尿症(msud)の処置のおける使用のための酵素の生合成 Pending JP2022537214A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962864875P 2019-06-21 2019-06-21
US201962865129P 2019-06-21 2019-06-21
US62/865,129 2019-06-21
US62/864,875 2019-06-21
PCT/US2020/038813 WO2020257707A1 (en) 2019-06-21 2020-06-19 Biosynthesis of enzymes for use in treatment of maple syrup urine disease (msud)

Publications (3)

Publication Number Publication Date
JP2022537214A JP2022537214A (ja) 2022-08-24
JP2022537214A5 true JP2022537214A5 (https=) 2023-06-27
JPWO2020257707A5 JPWO2020257707A5 (https=) 2023-06-27

Family

ID=74037433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576258A Pending JP2022537214A (ja) 2019-06-21 2020-06-19 メープルシロップ尿症(msud)の処置のおける使用のための酵素の生合成

Country Status (9)

Country Link
US (2) US20220348933A1 (https=)
EP (2) EP3986432A4 (https=)
JP (1) JP2022537214A (https=)
KR (1) KR20220042350A (https=)
CN (1) CN114450403A (https=)
AU (1) AU2020297586A1 (https=)
CA (1) CA3144416A1 (https=)
IL (1) IL289123A (https=)
WO (2) WO2020257610A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US20220031771A1 (en) * 2020-07-31 2022-02-03 Iowa State University Research Foundation, Inc. Microencapsulated and chromosome integrated compositions for l-dopa microbiome therapy
CN113484435B (zh) * 2021-07-05 2023-04-07 中国人民解放军空军军医大学 检测血浆支链氨基酸和支链a酮酸水平的物质的应用及产品
WO2024064918A2 (en) * 2022-09-23 2024-03-28 Novome Biotechnologies, Inc. Recombinant fusion polypeptides for secreting soluble, heterologous cargo
WO2025046062A1 (en) 2023-08-31 2025-03-06 Snipr Biome Aps A novel type of crispr/cas system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6119738B2 (ja) * 2012-03-30 2017-04-26 味の素株式会社 改変ロイシン脱水素酵素
WO2014028642A1 (en) * 2012-08-17 2014-02-20 Easel Biotechnologies, Llc Two stage production of higher alcohols
US10059969B1 (en) * 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
US10610546B2 (en) * 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
CN104774813B (zh) * 2015-04-20 2019-02-26 南京工业大学 一种亮氨酸脱氢酶及其制备方法和应用
IL256216B (en) * 2015-06-10 2022-07-01 Synlogic Operating Co Inc Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2017123676A1 (en) * 2016-01-11 2017-07-20 Synlogic, Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
CN108103038B (zh) * 2017-12-15 2021-03-02 江南大学 一种合成l-苯甘氨酸的单细胞工厂及其构建与应用
CN108559735B (zh) * 2018-05-10 2020-07-07 江南大学 一种亮氨酸脱氢酶突变体的构建及其应用
CN109321538A (zh) * 2018-09-07 2019-02-12 江南大学 一种基于数据库基因挖掘方法获得的亮氨酸脱氢酶
CN109679978B (zh) * 2018-12-12 2020-12-29 浙江工业大学 一种用于制备l-2-氨基丁酸的重组共表达体系及其应用
WO2021146394A1 (en) * 2020-01-14 2021-07-22 Synlogic Operating Company, Inc. Optimized bacteria engineered to treat disorders involving the catabolism of leucine, isoleucine, and/or valine

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022537214A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
CL2025004053A1 (es) Tapa, combinación de recipiente y tapa, y recipiente con tapa.
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)